Table 1.
Characteristics and validation of the new line iPSCs RAUi002-A.
| Classification | Test | Result | Data |
|---|---|---|---|
| Morphology | Photography Bright field | Normal | Figure 1A |
| Pluripotency status | Qualitative analysis: Alkaline phosphatase staining | Positive | Figure 1B |
| Qualitative analysis: Immunocytochemistry | Positive staining for pluripotency markers: OCT3/4, SOX2, NANOG, SSEA-4 | Figure 1C | |
| Quantitative analysis: RT-qPCR | Expression of pluripotency markers: NANOG, OCT4, SOX2 | Figure 1D | |
| Genotype | Karyotype (G-banding) | 46,XY | Figure 1E |
| Mutation analysis | Sanger sequencing of DNA from patient’s PBMCs and iPSCs | Homozygous p.M694V (c.2080A>G, rs61752717) in exon 10 of the MEFV gene | Figure 1H |
| Differentiation potential | Embryoid body formation | Positive staining for germ layer markers: ɑSMA and CD29 (mesoderm); MAP2 and TUBB3/TUJ1 (ectoderm); CK18/AFP (endoderm) | Figure 1G |
| Specific pathogen-free status | Mycoplasma | Negative | Figure 1I |